Celgene Corporation (CELG) Shares are Down -3%

Celgene Corporation (CELG) : During the past 4 weeks, traders have been relatively bearish on Celgene Corporation (CELG), hence the stock is down -2.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.36% relative to the S&P 500. The 4-week change in the price of the stock is -3.03% and the stock has fallen -3% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 4.01% and the fifty day Moving Average is 1.99%. Celgene Corporation is up 2.22% in the last three month period. Year-to-Date the stock performance stands at -9.16%.

Celgene Corporation (CELG) : 14 investment research analysts covering Celgene Corporation (CELG) have an average price target of $141.79 for the near short term. The highest target price given by the Brokerage Firm to the stock is $162 and the lowest target is $120 for the short term. Analysts expect the variance to be within $12.26 of the average price.


Celgene Corporation (NASDAQ:CELG): stock turned positive on Friday. Though the stock opened at $107.93, the bulls momentum made the stock top out at $110.13 level for the day. The stock recorded a low of $107.5 and closed the trading day at $108.79, in the green by 0.82%. The total traded volume for the day was 4,728,358. The stock had closed at $107.91 in the previous days trading.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.